Confidential Information Summary
Executive summary
Pharmora markets branded formulations in India through physician detailing, stockists and online pharmacy listings. It owns the brands, dossiers and trade relationships but no plant; licensed third-party manufacturers make every product.
The proprietor is retiring with no successor and offers 100% of the business to a pharmaceutical buyer, an aggregator or a healthcare operator.
Turnover fell in both years shown while margins rose, so the underwriting question is how much of the base survives a change of owner.
At a glance
Basis of preparation. Figures are management's, in ₹ lakh (L), for the sole proprietorship on one standalone basis: gross turnover and operating EBITDA. The documents do not state whether FY2023-24 to FY2025-26 are audited, or whether turnover is before or after GST.
FY2026-27 is a part-year with no stated cut-off. Gross margins are management's approximations. Depreciation, tax, cash flow and balance sheet were not provided.
Investment highlights
Wide, chronic-led portfolio
Diabetes, hypertension and cardiac lines are repeat-prescription categories, alongside nutraceutical, anti-infective and gastro lines.
35+ formulationsRegistered trademarks
Management reports clean registered marks across the diabetes, cardiac, gastro and neuro-nutrition lines. Registration certificates are for diligence.
6 named marksAsset-light cost base
No machinery, no factory depreciation and no long-term debt. Capacity sits with licensed contract manufacturers.
Nil long-term debtMargins held as sales fell
Gross margin rose each year while turnover declined, so the cost side has been managed; see section 08.
Gross margin +4 pts, FY24–26Complete exit with handover
The promoter offers all brands, dossiers, stockist registers and vendor portals, with a transition period.
3–6 month handoverBusiness overview
The business has operated for over three decades as an ethical pharmaceutical marketer. It has run in maintenance mode, with no sales-force expansion in the years shown.
Diabetes
Glimepiride, metformin SR, pioglitazone and teneligliptin combinations.
Hypertension & cardiac
Telmisartan and metoprolol succinate, alone and with amlodipine or HCTZ.
Nutraceuticals & wellness
Vitamin D3, calcium, B-complex, iron, zinc and digestive enzymes.
Anti-infectives
Cefpodoxime proxetil, with and without clavulanate, in tablet and dry-syrup forms.
Gastro & pain
Pantoprazole combinations, an NSAID-enzyme combination, and laxatives.
Revenue by category was not provided and will be supplied in the data room.
Business model & economics
Revenue comes from three channels, all selling products made by others. Margin is earned on brand and distribution, not on manufacturing.
Prescriptions from consulting physicians, diabetologists and cardiologists.
Wholesale distribution in central and north-west India and adjacent territories.
Active catalogue listings on a large online pharmacy platform.
| Channel | Revenue share | Terms |
|---|---|---|
| Ethical detailing | Not provided | Not provided |
| Stockists & wholesale | Not provided | Not provided |
| E-pharmacy | Not provided | Not provided |
Regulatory position
The regulatory value is in the marks, product dossiers and the licences the business itself holds. Plant approvals sit with the contract manufacturers, not the business.
What management reports
A buyer will need the product-wise approval schedule, trademark registration status and the loan-licence agreements before any exclusivity or price discussion.
Customer mix & concentration
Customers are prescribing physicians, retail chemists and stockists, plus online platform buyers. Repeat orders follow repeat prescriptions.
No customer-level data was provided. The concentration chart, masked top-20 table and movement chart cannot be built, and nothing has been estimated. Account-level billings for at least three years will be provided in the data room.
This is the first item a buyer will test, because stockist concentration decides how much turnover survives the transition.
The base, in numbers
Financial snapshot
Turnover has declined in each year shown. Margins moved the other way.
The table shows turnover, margin and EBITDA for three full years and the part-year.
| FY24 | FY25 | FY26 | FY27 YTD | |
|---|---|---|---|---|
| Gross turnover | 120.4 | 104.8 | 96.6 | 47.1 |
| Change | — | −12.9% | −7.8% | n/a |
| Gross margin (approx.) | ~48% | ~50% | ~52% | ~52% |
| Operating EBITDA | 19.2 | 17.3 | 17.4 | 8.5 |
| EBITDA margin | 16.0% | 16.5% | 18.0% | 18.0% |
Balance sheet
A two-year CAGR of −10.4%. Management's relaunch targets (₹250 L in Year 1, ₹850 L in Year 3) are its own, not a forecast and not validated by the adviser. No order book supports them and they carry no weight in valuation until tested.
Weakest metric. Turnover is down ₹23.8 L in two years. The cause, whether lost stockists, lapsed detailing or price, is not explained in the documents.
Quality of earnings
EBITDA here is management's operating figure for the proprietorship; whether it is stated after the proprietor's own drawings is not disclosed.
Gross margin rose about four points over two years, yet EBITDA fell from ₹19.2 L to ₹17.4 L (−9.4%). The margin gain therefore offset only part of the lost turnover, and the EBITDA margin rose because turnover fell faster than costs.
Items assessed
It closed about six months ago. The FY27 part-year is fresher, but its cut-off date and a monthly sales ledger are needed.
Management & organisation
The business is the promoter. No employee, field-force or finance-function data was provided.
| Role | Holder | Status |
|---|---|---|
| Proprietor | Promoter (1) | Over three decades' experience; retiring |
| Detailing & sales | Not provided | No expansion in years shown |
| Manufacturing | Contract manufacturers | Licensed, third-party |
| Finance & compliance | Not provided | — |
Key-man. Physician and stockist relationships rest with Promoter (1), who commits to a 3–6 month handover. There is no successor, so the handover period sets how much of the base transfers.
M&A proposition
The offer is the whole business: marks, dossiers, marketing rights, stockist registers and vendor portals. A majority partnership is also open.
Promoter is at retirement age with no family successor.
No sales-force expansion in the years shown; management sees reactivation headroom.
Wellness lines can be relaunched under new branding on online channels.
Transaction parameters
Buyer profile
Pharma marketers, aggregators and healthcare entrepreneurs seeking established brands.
Value-creation levers
Reactivate lapsed stockists, rebrand wellness lines for online sale, and add contract-made exports.
Use of proceeds. Not applicable: this is a full exit and the proceeds go to the promoter. Management's levers are untested and carry no weight in valuation.
Risks & mitigants
Turnover declined 19.7% in two years
The cause is unexplained. Mitigant: monthly sales by product and stockist will be in the data room; price should reflect FY27 run-rate, not FY24.
Customer concentration unknown
No account data exists in the file. Mitigant: account-level billings for three years will be provided before any offer.
Promoter dependence
Relationships are personal and there is no successor. Mitigant: a 3–6 month handover is committed; joint stockist and physician introductions can be tested during it.
Single-source manufacturing
All products are made under loan licences. Mitigant: agreements, tenure and transfer terms to be reviewed; a second source can be qualified.
Licences and marks may not transfer
A sole proprietorship's licences are personal. Mitigant: the marks move by assignment deed; the buyer should plan fresh licences and confirm registration status.
Earnings basis unverified
Audit status, GST basis and proprietor remuneration are unstated. Mitigant: audited accounts and a normalised EBITDA to be supplied.
Relaunch targets unsupported
No order book or plan backs them. Mitigant: they are excluded from this document's analysis; a buyer should build its own case.
Process & next steps
Enquiries go to CA Dhiraj Ostwal & Co. — Transaction Advisory, quoting project code SE-042. Identity is disclosed only after an NDA.
Disclaimer. This summary was prepared by CA Dhiraj Ostwal & Co. from information supplied by the seller. It is for discussion only, is not an offer or invitation to buy or sell any asset, and is not investment, legal or tax advice. The information has not been independently verified, and no representation or warranty is given as to its accuracy or completeness. Figures are management's. Statements about the future are management's views, not forecasts. Recipients must make their own enquiries and rely on definitive agreements. The adviser and the seller accept no liability for any loss arising from its use. This document is confidential and may not be copied or shared.